Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare ConferenceSouth San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology
company focused on the discovery and development of novel antibodies for the potential
treatment of a broad range of diseases, today announced that the company’s management team
will present a company overview at the Lazard Capital Markets 9th Annual Healthcare
Conference on Wednesday, November 14, 2012 at 2:00 p.m. Eastern Time at the Pierre Hotel in
New York, NY.
About Prothena Corporation
Prothena Corporation is a biotechnology company focused on the discovery and development of
novel antibodies for the potential treatment of a broad range of diseases that involve protein
misfolding or cell adhesion. Prothena focuses on the discovery and development of potential
therapeutic monoclonal antibodies directed specifically to disease causing proteins. These
potential therapies have a broad range of indications including AL and AA forms of amyloidosis,
Parkinson’s disease and related synucleinopathies, and novel cell adhesion targets involved in
autoimmune disease and metastatic cancers. Prothena’s strategy is to apply our extensive
expertise in generating novel therapeutic antibodies and work with collaborators having expertise
in specific animal models of disease, to identify antibody candidates for clinical development.
For more information, please visit www.neotopebio.com.
Paul Cox, Stern Investor Relations, Inc.